Kenvue reported higher profit and revenue, boosted by strength in its self care and essential health divisions.
The results come as the maker of over-the-counter health products works to turn around its business ahead of its $40 billion acquisition by consumer-products company Kimberly-Clark.
The Tylenol and Listerine maker posted a third-quarter profit of $430 million, or 22 cents a share, compared with $398 million, or 21 cents a share, a year earlier.
Adjusted earnings per share were 29 cents, in line with analyst estimates, according to FactSet.
Revenue increased 3.2% to $3.89 billion, compared with analyst estimates of $3.86 billion.
On an organic basis, sales rose 2.9%, with increases in the company's self care and essential health units. Organic sales ticked down in its skin health and beauty division.
Chief Executive Kirk Perry said the results marked a fourth consecutive quarter of net and organic sales growth, thanks to Kenvue's ongoing productivity efforts and investments in its brands and innovation.
"We are strongly on track to deliver our business transformation that we began last year," Perry said.
Kimberly-Clark agreed to buy Kenvue last year. The companies have previously said they expect the deal to close in the fourth quarter of this year.
Comments